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CABG = coronary artery bypass grafting; CI = cardiac index; CPB = cardiopulmonary bypass; HR = heart rate; ICG = indocyanine green; ICU =
intensive care unit; IMA = internal mammary artery; LCOS = low cardiac output syndrome; LVEF = left ventricular ejection fraction; MAP = mean
arterial pressure; NO = nitric oxide; PDI = phosphodiesterase inhibitor; pHi = intramucosal pH; PVR = pulmonary vascular resistance; SVR = sys-
temic vascular resistance; SVI = stroke volume index.
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Abstract
Many adult patients require temporary inotropic support after
cardiac surgery. We reviewed the literature systematically to
establish, present and classify the evidence regarding choice of
inotropic drugs. The available evidence, while limited in quality and
scope, supports the following observations; although all β-agonists
can increase cardiac output, the best studied β-agonist and the
one with the most favourable side-effect profile appears to be
dobutamine. Dobutamine and phosphodiesterase inhibitors (PDIs)
are efficacious inotropic drugs for management of the low cardiac
output syndrome. Dobutamine is associated with a greater
incidence of tachycardia and tachyarrhythmias, whereas PDIs often
require the administration of vasoconstrictors. Other catechol-
amines have no clear advantages over dobutamine. PDIs increase
the likelihood of successful weaning from cardiopulmonary bypass
as compared with placebo. There is insufficient evidence that
inotropic drugs should be selected for their effects on regional
perfusion. PDIs also increase flow through arterial grafts, reduce
mean pulmonary artery pressure and improve right heart
performance in pulmonary hypertension. Insufficient data exist to
allow selection of a specific inotropic agent in preference over
another in adult cardiac surgery patients. Multicentre randomized
controlled trials focusing on clinical rather than physiological
outcomes are needed.
Introduction
Despite improvements in surgical technique and myocardial
protection, pharmacological support for low cardiac output is
often required during and after weaning from cardio-
pulmonary bypass (CPB) [1]. This acute deterioration in
ventricular function may continue into the postanaesthesia
care unit or intensive care unit (ICU). Because cardiac
surgery is conducted in an increasingly aged population, with
coexisting pathology, these patients are at increased risk for
developing a low cardiac output syndrome (LCOS) during
the postoperative period.
There is no consensus definition of what constitutes LCOS,
but it would be reasonable to define it as a low cardiac output
(cardiac index [CI] <2.4 l/min per m2 is used as a criterion in
some studies) with evidence of organ dysfunction, for
example elevated lactate or urine output under 0.5 ml/hour for
more than 1 hour. Such LCOS can persist for several hours
to days, despite optimization of volume status, temporary
pacing, or exclusion of mechanical factors (e.g. cardiac
tamponade and mechanical assistance with intra-aortic
balloon counter-pulsation). Causes are multifactorial but
include myocardial ischaemia during cross-clamping, reper-
fusion injury, cardioplegia-induced myocardial dysfunction,
activation of inflammatory and coagulation cascades, and un-
reversed pre-existing cardiac disease. LCOS can result in
reduced oxygen delivery to vital organs [2]. Organ
dysfunction and multiple organ failure are among the main
causes of prolonged hospital stay after cardiac surgery, and
this increases resource use and health care costs as well as
increasing morbidity and mortality. Optimization of cardiac
output and oxygen delivery may decrease morbidity and
reduce length of stay [3].
Review
Bench-to-bedside review: Inotropic drug therapy after adult
cardiac surgery – a systematic literature review
Michael Gillies1, Rinaldo Bellomo1, Laurie Doolan2 and Brian Buxton3
1Department of Intensive Care and Medicine (University of Melbourne), Austin Hospital, Melbourne, Australia
2Department of Anaesthesia, Austin Hospital, Melbourne, Australia
3Department of Cardiac Surgery, Austin Hospital, Melbourne, Australia
Corresponding author: Rinaldo Bellomo, rinaldo.bellomo@austin.org.au
Published online: 16 December 2004 Critical Care 2005, 9:266-279 (DOI 10.1186/cc3024)
This article is online at http://ccforum.com/content/9/3/266
© 2004 BioMed Central Ltd
See commentary, page 241 [http://ccforum.com/content/9/3/241]267
Available online http://ccforum.com/content/9/3/266
Despite a wide range of available inotropic agents, no
consensus exists regarding the treatment of LCOS post-
CPB. This review examines the pharmacological options for
providing inotropic support in the period after CPB and
evaluates the literature systematically in order to establish,
present and classify the available evidence regarding the use
of inotropic drugs after cardiac surgery in adults. We do not
discuss exclusive or mostly vasopressor drugs such as
vasopressin and norepinephrine (noradrenaline).
Methods
We conducted a systematic Medline and PubMed search,
over the period 1982–2003, using the following keywords:
cardiac surgery, cardiopulmonary bypass, coronary artery
bypass grafting, inotropic support, epinephrine, dopamine,
dopexamine, dobutamine, amrinone, enoximone, milrinone
and levosimendan. Agents considered to be primarily vaso-
pressors (e.g. norepinephrine, arginine vasopressin and
phenylephrine) and mechanical support (e.g. intra-aortic
balloon counter-pulsation and assist devices) are not
considered. For reasons of space and the likelihood that they
would behave like other agents in their class, the more
obscure phosphodiesterase inhibitors (PDIs; e.g. olprinone)
not in common usage in the UK and Australia are not
considered.
The bibliographies of articles identified through this
methodology were also studied for reports that might have
been missed in our initial searching of electronic reference
libraries. Non-English language papers, animal studies,
paediatric studies and in vitro studies are not included. Using
this search strategy we identified 210 papers. This selection
was further refined to 142 reports in which the agent in
question was used for support of cardiac function or vital
organ perfusion in patients who had undergone cardiac
surgery. All articles in question were obtained.
Papers were selected and graded for quality of evidence
according to the methodology of Cook and coworkers [4]
(Table 1). Particular attention was given to the following
issues regarding each agent in patients who have undergone
cardiac surgery: what are the effects of each inotropic drug
on systemic haemodynamics?; does the inotropic drug alter
vital organ perfusion?; does the inotropic drug affect major
clinical outcomes (e.g. time spent in hospital or ICU or
requiring ventilation or artificial renal support) or survival?;
and does the inotropic drug have any important side effects?
Data covering the application of each therapy were examined.
Where possible, ‘evidence-based’ recommendations were
developed.
Results
The results of our literature search are considered by
pharmacological groups and agent. A full pharmacological
profile of each agent is beyond the scope of the present
review, but the proposed cellular mechanisms of action and
receptor activation for each agent are schematically
summarized in Fig. 1.
Catecholamines
Natural and synthetic catecholamines have different haemo-
dynamic effects because of their differential abilities to
stimulate adrenergic receptors. Accordingly, each must be
considered separately.
Epinephrine
Epinephrine (adrenaline) is a naturally occurring catechol-
amine that binds to both α- and β-receptor subgroups, with β
effects predominating at low doses and α effects
predominating at high dose. Fifteen reports relating to the use
of epinephrine in cardiac surgical patients were retrieved
using our search strategy. No study yielding ‘level I’ evidence
(Table 1) was identified. Only one uncontrolled study, that by
Gunnicker and coworkers [5], specifically investigated its
effectiveness in LCOS.
In that report [5], epinephrine at a dose of 0.03 µg/kg per min
produced significant increases in CI and heart rate (HR) of
24.1% and 14.1%, respectively, compared with placebo. HR
was minimally affected in all studies except that of Gunnicker
and coworkers, in which it increased by 14%. All studies
recorded significant increases in mean arterial pressure
(MAP) [6]. A recent observational study on the effects of 5 µg
boluses in patients undergoing cardiac surgery [7] revealed a
biphasic effect on systemic vscular resistance (SVR), with an
initial increase followed by reduction.
Epinephrine has also been directly compared with amrinone,
milrinone and dobutamine. Two small, randomized controlled
trials [5,8] compared epinephrine with the PDI amrinone. In
both studies, both drugs significantly increased CI from
baseline. In the randomized, open-label trial conducted by
Gunnicker and coworkers [5] in 20 patients with LCOS,
Table 1
Grading of responses to questions and levels of evidence
Details
Levels of evidence
I Randomized trials with low α error (< 0.05) and β error (< 0.8)
II Randomized trials with high α error or low power
III Nonrandomized, concurrent cohort studies
IV Nonrandomized, historic cohort studies
V Case series
Grading of responses to questions
A Supported by at least two level I investigations
B Supported by only one level I investigation
C Supported by level II investigations only
D Supported by at least one level III investigation
E Supported by level IV or V evidence268
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epinephrine produced a significantly greater increase in CI,
HR and MAP than did amrinone. However, this was
accompanied by significantly greater increases in myocardial
workload and oxygen consumption. Lobato and coworkers
[9] conducted a prospective, randomized, blinded trial
comparing the myocardial relaxation effects of epinephrine
with those of milrinone in patients undergoing elective
coronary artery bypass grafting (CABG). Epinephrine
(0.03 µg/kg per min) had no effect on left ventricular end-
diastolic area, as measured using trans-oesophageal
echocardiography, whereas milrinone significantly increased
it by 15%. Two studies [10,11] compared epinephrine with
dobutamine and found epinephrine to be less effective at
increasing CI than dobutamine over what the authors
considered a reasonable clinical range of doses
(0.01–0.03 µg/kg per min for epinephrine and 2.5–5 µg/kg
per min for dobutamine). However, dobutamine was
associated with significantly more tachycardia for the same
stroke volume index (SVI).
No studies were found regarding the effect of epinephrine on
blood flow to vital organs. A prospective, randomized trial
[12] showed that epinephrine produces lactic acidosis in
some post-CPB patients.
Two randomized controlled trials, one of which used laser
Doppler flowmetry, investigated the effect of epinephrine on
internal mammary artery (IMA) graft flow [13,14]. Both of
these studies found epinephrine to have no effect on IMA
blood flow. An earlier crossover study of 28 patients [15],
Figure 1
Schematic representation of the postulated mechanisms of intracellular action of catecholamines and phosphodiesterase inhibitors (PDEIs).
Catecholamines activate β- or α-adrenergic receptors, which in turn are linked with different G regulatory proteins. The β-receptor is linked with a
stimulatory Gs-guanidine triphosphate unit (Gs-GTP), which activates the adenyl cyclase system resulting in increased concentrations of cyclic
AMP (C-AMP), which in turn activate calcium channels to lead to increased cytosolic calcium, which increases the contractility of the actin–myosin
system through its binding with troponin C. Depending on the concentration of a C-AMP-dependent protein kinase, phospholambam is
phosphorylated and the uptake of calcium by the sarcoplasmic reticulum (SR) is also affected. The concentration of C-AMP in the myocardium is
also regulated by the activity of the type III phosphodiesterase enzyme. If this is inhibited by a PDEI, then C-AMP concentration rises, with effects
on cytosolic calcium concentration. In the myocardium this leads to increased contractility, and in vascular smooth muscle to vasodilatation. The α-
adrenergic receptor, on the other hand, activates a different regulatory G protein (Gq), which acts through the phospholipase C system and the
production of 1,2-diacylglycerol (DAG) and, via phosphatidyl-inositol-4,5-biphosphate (PiP2), of inositol 1,4,5-triphosphate (IP3). IP3 activates the
release of calcium from the SR, which by itself and through the calcium–calmodulin dependent protein kinases influences cellular processes, which
in vascular smooth muscle leads to vasoconstriction. DAG simultaneously activates protein kinase C, which leads to the phosphorylation of other
proteins within the cell.
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using an electromagnetic flowmeter, had shown that
epinephrine significantly increased flow through IMA and
saphenous vein grafts.
No studies were found regarding the effect of epinephrine on
major clinical outcomes or survival.
Dopamine
Dopamine is a naturally occurring catecholamine that binds to
both  α- and β-receptor subgroups, with β effects
predominating at low dose and α effects predominating at
high dose. Doses of 2–10 µg/kg per min are commonly used
for inotropy, with doses of 1.5–3.0 µg/kg per min still used by
some for renal protection (‘renal dose’) because of the
binding of the drug to specific dopaminergic receptors in the
kidney. Our literature search identified a total of 21 papers
relating to the use of dopamine in cardiac surgical patients,
all of which were retrieved.
None of these papers specifically compared the haemo-
dynamic effects of dopamine with those of placebo. When
the effects of dopamine on CI were compared with baseline
data, dopamine at a dose of between 2.5 and 5.0 µg/kg per
min produced significant increases in CI (range 16.3–57.9%).
In all studies except one there was a significant rise in HR
(range 4.5–45.7%).
At doses of up to 5 µg/kg per min, significant decreases in
SVR (range 13.1–46.1%) were recorded. However, in 1982
Saloman and coworkers [16] conducted a prospective,
randomized, blinded trial of 20 patients and found that
increasing dopamine from 5.0 to 7.5 µg/kg per min caused
significant increases in MAP and pulmonary vascular
resistance (PVR) without increasing cardiac output. In a
multicentre, prospective, blinded, randomized trial of 70
patients, Rosseel and coworkers [17] examined the use of
dopamine in LCOS after cardiac surgery. The study
compared dopamine with dopexamine in patients with CI
below 2.2 l/min per m2. Dopamine produced a 57.9%
increase in CI compared with baseline. However, this was
accompanied by a 25.5% increase in HR. Clinical efficacy
(defined as CI >2.5 l/min per m2 and urine output >0.5 ml/kg
per hour) was significantly greater in the dopexamine group at
1–2 hours after commencement of the infusion and
approached significance at other time points. Moreover, 63%
of patients in the dopamine group had an adverse cardiac
event (defined as arrhythmias, ischaemia and hypertension),
which was significantly greater than with dopexamine.
Tarr and coworkers [18] compared the efficacies of
dopamine, dobutamine and enoximone for weaning from CPB
in a randomized trial of 75 patients. Nine of the 25 patients
randomly assigned to dopamine failed to respond adequately,
and the remaining 16 recorded an increase in CI of 25.7%
but this was accompanied by an increase in HR of 44.3%,
with little change in SVI. The CI in the dopamine treated
group was significantly lower than in patients treated with
either dobutamine or enoximone.
Dopamine has been studied extensively with regard to
regional perfusion of the gut and kidney. Other than a case
series of 15 patients reported by Davis and coworkers in
1982 [19], which suggested that low-dose dopamine might
increase postoperative urine output and serum creatinine in
CPB patients, several level II studies [20–23] have failed to
provide any evidence to support its use. Jakob and coworkers
[24,25] and Thoren and colleagues [26] conducted
observational studies on the effect of dopamine on
splanchnic perfusion using indocyanine green (ICG) dye
clearance and laser Doppler flowmetry, respectively. They
observed significant increases in splanchnic blood flow in the
order of 27–36%. Two level II studies [27,28] failed to
demonstrate any effect of dopamine on gastric intramucosal
pH (pHi). A significant worsening in pHi associated with low
CPB flow rate and dopamine was observed by Schneider
and coworkers [29] in a randomized, double-blind, placebo-
controlled trial (n = 100) conducted in 1998.
No data were found regarding the effect of dopamine on
major clinical outcomes or survival.
Dobutamine
Dobutamine is a synthetic catecholamine and is a derivative
of isoprenaline. It has strong affinity for β-receptors with
little affinity for α-receptors because of the configuration of
the terminal amine. Twenty-six studies investigating the
effects of dobutamine in cardiac surgical patients were
identified and retrieved. These studies are summarized in
Table 2.
Administration of dobutamine in cardiac surgery patients
produces a dose-dependent rise in CI. In the study
conducted by Ensinger and coworkers [31], in which they
compared dobutamine at 6.0 µg/kg per min with placebo, a
significant increase in CI of 46% was recorded. Studies by
Feneck and coworkers [2] and Tarr and colleagues [18],
investigating the haemodynamic effects of dobutamine in
LCOS, identified increases in HR in excess of 25%.
Significant reductions in SVR (>40% in the study by Tarr and
coworkers) were also recorded.
Romson and coworkers [32] conducted an observational
study of 100 patients who had undergone cardiac surgery
and were administered dobutamine at doses of 0–40 µg/kg
per min, where tolerated, and compared these with 10
control patients who received no dobutamine. Those
investigators found that HR increased by an average of
1.45 beats/min per µg/kg per min in patients who were able
to receive the full dose (66 out of 100 patients). Of the
patients who were unable to receive the full dose, more than
half (52%) developed tachycardia greater than 85% of
predicted maximum HR by age. Romson and coworkers
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concluded that, in post-CPB patients, the dominant method
of increasing CI was by increasing HR.
The Milrinone Multicentre Trial Group provided the most
recent randomized controlled trial data concerning
dobutamine [2]. That multicentre, randomized but not blinded
study compared the haemodynamic effects of dobutamine
with those of milrinone. A total of 120 patients with CI below
2.0 l/min per m2 were studied and dobutamine was used at
doses of 10–20 µg/kg per min. Dobutamine increased CI by
55% versus 36% with milrinone at 1 hour, and this effect was
accompanied by a 35% increase in HR (versus 10% with
milrinone) and a 31% increase in MAP (versus 7% with
milrinone). Dobutamine was also associated with significantly
higher incidences of hypertension and new atrial fibrillation
(18% versus 5%; P < 0.04).
The randomized trial of 75 patients conducted by Tarr and
coworkers in 1993 [18] identified no statistically significant
difference in CI between enoximone and dobutamine (both
drugs effectively increased CI). However, dobutamine
produced significantly more tachycardia, and enoximone
Critical Care    June 2005 Vol 9 No 3 Gillies et al.
Table 2
Summary of literature search results for dobutamine
Dose (µg/kg 
Ref. n Year Study design Level of evidence Comparator per min) End-points
[2]a,b 120 2001 Multicentre, prospective,  II Milrinone 10–20 Haemodynamic parameters
unblinded, randomized trial
[26] 10 2000 Prospective, blinded, randomized,  III Dopamine, dopexamine 2.7 Jejunal perfusion
crossover study
[30]a 64 2000 Prospective, blinded, randomized,  II Placebo, ranitidine 4.0 pHi
controlled trial
[31]a 17 1999 Prospective, blinded, randomized,  II Placebo 6.0 Haemodynamic parameters,
controlled trial splanchnic blood flow
[32]a 110 1999 Observational study III – 0–40 Haemodynamic parameters
[14] 30 1997 Prospective, blinded, randomized trial II Enoximone, epinephrine 3.0 IMA graft flow
[33]a,c 20 1997 Prospective, unblinded, randomized trial II Enoximone 8.0 Haemodynamic parameters
[34]c 20 1997 Prospective, blinded, randomized trial II Enoximone 5.0 Haemodynamic parameters
[35]a,b 30 1996 Prospective, blinded, randomized trial II Enoximone 10.0 Haemodynamic parameters
[36]a,b 28 1995 Prospective, unblinded, randomized  II Control 4.4 Haemodynamic parameters, 
controlled trial pHi, ICG Clearance
[37]a,b 10 1994 Prospective, blinded, randomized trial II Dopexamine 5.0–10.0 Haemodynamic parameters
[18]c 75 1993 Prospective, blinded, randomized trial II Enoximone, dopamine 5.0 Haemodynamic parameters
[38]a,b 16 1993 Prospective, unblinded, nonrandomized  III Sodium nitroprusside,  Haemodynamic parameters 
controlled trial control ICG Clearance
[10] 52 1992 Observational study III Epinephrine 2.5–5.0 Haemodynamic parameters
[39]a,b 30 1992 Prospective, unblinded, randomized trial II Amrinone 5–15 Haemodynamic parameters
[40] 10 1992 Observational study III Various dose ratios of  0–10.0 Haemodynamic parameters
dopamine/dobutamine
[41]a 20 1990 Prospective, unblinded, randomized trial II Enoximone 5.0 Haemodynamic parameters
[42]a 20 1990 Prospective, unblinded, randomized trial II Enoximone 10.0 Haemodynamic parameters
[43]a,b 40 1990 Prospective, unblinded, randomized trial II Enoximone 5–7 Haemodynamic parameters
[44]a 50 1990 Prospective, unblinded, randomized trial II Enoximone 5.0 Haemodynamic parameters
[11]a 16 1986 Prospective, unblinded, randomized, trial II Epinephrine 4.8 Haemodynamic parameters
[45]a,b 9 1986 Sequential, cross-over study III Dopamine 5–10.0 Haemodynamic parameters
[16] 20 1982 Prospective, blinded, randomized trial II Dopamine 2.5–10.0 Haemodynamic parameters
aPostoperative support. bCardiac index <2.5 l/min per m2 or preoperative left ventricular ejection fraction <0.4. cWeaning from cardiopulmonary
bypass. ICG, indocyanine green; IMA, internal mammary artery; pHi, intramucosal pH.271
produced significantly greater increases in SVI. A further five
small randomized trials compared dobutamine with
enoximone [33,41–44], but only one of these studies [44]
demonstrated any difference between drugs, specifically a
significantly greater increase in CI in the enoximone-treated
group.
Two small randomized trials [34,39] compared dobutamine
with amrinone and found no significant differences in
haemodynamic effect. Dupuis and coworkers [39], however,
did note an increase in incidence of arrhythmias in the
dobutamine group, and 40% of patients treated with
dobutamine suffered postoperative myocardial infarction
versus none in the amrinone group (P = 0.017).
Regarding comparisons with other catecholamines,
MacGregor and coworkers [37] conducted a randomized,
blinded comparison of dopexamine and dobutamine in 10
patients undergoing CABG. No significant differences in
haemodynamic variables were found, but there was a
significantly greater incidence of supraventricular tachy-
cardias in the dopexamine group. As mentioned above,
Butterworth and coworkers [10] found no significant
differences between epinephrine and dobutamine other
than a significantly greater HR in the dobutamine-treated
group.
Six studies investigated the effects of dobutamine on regional
perfusion. The study by MacGregor and coworkers [37],
outlined above, showed no difference in net sodium excretion
or urinary output compared with dopexamine. The remaining
studies investigated the effects of dobutamine on splanchnic
blood flow. Four studies demonstrated significant increases
in splanchnic blood flow as measured by ICG clearance
[31,36,38] or laser Doppler flowmetry [26]. In studies in
which pHi was measured, dobutamine had no effect [31,34]
or decreased pHi [36].
We were unable to find any data relating to the effect of
dobutamine on major clinical outcomes or survival.
Dopexamine
Dopexamine is a synthetic catecholamine with agonist activity
at  β2-receptors and indirect action at β1-receptors by
inhibiting the uptake of endogenous catecholamines [46].
This agent is not available in some developed countries. Our
literature search identified 20 papers investigating the effects
of dopexamine in patients who had undergone cardiac
surgery, all of which were retrieved.
Two randomized controlled trials [47,48] compared
dopexamine with placebo. Hurley and coworkers [47]
reported a study of 23 low-risk post-CABG patients in 1995.
In that study, dopexamine at a dose of 2.0 µg/kg per min
significantly increased CI by 41% and HR by 19%. SVR was
also reduced by 45%. In their randomized, double-blind,
placebo-controlled trial, Sherry and coworkers [48] similarly
found significant increases in HR and CI over placebo (one
patient was withdrawn from the study because of
tachycardia).
We identified five studies investigating the effects of
dopexamine in LCOS, the largest of which is the multicentre,
randomized, blinded comparison of dopexamine with
dopamine reported by Rosseel and coworkers [17]. In that
study, the increased CI in the dopexamine group was
accompanied by an increase in HR of 37%. As previously
discussed, there was significantly greater efficacy and fewer
adverse events in the dopexamine group (although 54% of
the dopexamine group still suffered an adverse cardiac event
in the form of arrhythmia or ischaemia).
McGregor and coworkers [37] conducted a prospective,
randomized, blinded comparison of dopexamine with
dobutamine (n = 10) in patients with LCOS after CABG.
They found no difference between the agents other than the
fact that tachycardia of greater than 120 beats/min was more
common in the dopexamine group.
We were unable to find any studies comparing dopexamine
with PDIs. One study, reported by Honkonen and coworkers
[49], compared dopexamine with iloprost (a prostacyclin
analogue) in a randomized, double-blind, crossover trial of 20
patients with total proximal occlusion of the right coronary
artery. Dopexamine increased right ventricular ejection
fraction significantly more than did iloprost at a dose of
0.68 µg/kg per min.
Eight studies investigated the effects of dopexamine on
regional perfusion. A randomized, placebo-controlled trial of
44 patients undergoing CABG conducted by Berendes and
coworkers [50] in 1997 found improvement in creatinine
clearance in the dopexamine-treated groups. However, four
subsequent small randomized trials [37,48,51,52] failed to
provide any evidence that the use of dopexamine improves
renal function or perfusion.
Berendes and coworkers [50] also assessed the effects of
dopexamine on splanchnic oxygenation in a randomized,
placebo-controlled trial of 44 patients with normal left
ventricular ejection fraction (LVEF; >0.5) who received
dopexamine at doses of 0.5, 1.0 and 2.0 µg/kg per min.
There was no difference in hepatic venous oxygenation, and
pHi decreased during and after CPB in all patients. A further
three randomized controlled trials [28,53,54] concluded that
dopexamine had no influence on pHi compared with
dopamine or placebo. Dopexamine has also been shown to
increase jejunal perfusion (as measured by laser Doppler
flowmetry) and ICG dye clearance [55].
No studies were found relating to the effect of dopexamine
on major clinical outcomes or survival.
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Phosphodiesterase inhibitors
The cardiac effects of PDIs are characterized by positive
inotropy and improved diastolic relaxation (lusitropy; Fig. 1).
These agents also cause potent vasodilation, with reductions
in preload, afterload and PVR. Acute tolerance is not a
feature.
Amrinone
Amrinone (known as inamrinone in North America) is a
bipyridine phosphodiesterase-III inhibitor. It is typically given
as a loading dose of 0.75–1.5 mg/kg, followed by an infusion
of 10 µg/kg per min. It has an elimination half-life of 3.5 hours
in post-CPB patients [56]. Our literature search identified 27
papers, all of which were retrieved. One of these studies
provided level I data regarding the use of amrinone in patients
who have undergone cardiac surgery [57].
Lewis and coworkers [57] reported a prospective,
randomized, placebo-controlled trial of 234 patients. In that
study the amrinone group received a bolus of 1.5 mg/kg
followed by an infusion of 10 µg/kg per min to wean from
CPB. Phenylephrine or glyceryl trinitrate were also used to
optimize perfusion pressure. Significantly fewer patients
failed to wean in the amrinone group than in the control group
(7% versus 21%; P = 0.002). Amrinone improved weaning
success regardless of LVEF, although this benefit was only
statistically significant in the group with a preoperative LVEF
greater than 55%.
Another randomized controlled trial was undertaken by
Ramsay and coworkers [58]. A total of 100 patients
undergoing CABG were randomly assigned to receive a
single bolus of 0.75 mg/kg amrinone (with no subsequent
infusion) or saline before separation from CPB. Haemo-
dynamic measurements were similar between the two groups
at all times, but the amrinone group received a higher dose of
phenylephrine. The authors of that study conceded that an
insufficient amrinone dose might explain the lack of
haemodynamic effect.
Of the remaining level II evidence available, Badner and
coworkers [59] also conducted a randomized, blinded,
placebo-controlled trial of 30 patients undergoing mitral valve
replacement in which amrinone at 2.0 mg/kg or placebo was
given before weaning from CPB. The amrinone group had a
significant increase in CI (52% versus 10%) and decreases
in SVR index (47% versus 10%), but there was no
statistically significant difference in requirement for other
inotropes or vasopressors between groups. Kikura and Sato
[60] conducted a randomized, blinded comparison of
amrinone, milrinone and placebo in 45 patients for weaning
from CPB. Compared with placebo, amrinone significantly
improved CI and SVI, and reduced dopamine requirements.
The remaining studies largely echo these findings. In two of
these studies [61,62], however, more than 50% of patients in
the amrinone group required concomitant infusions of
phenylephrine to maintain MAP.
Two studies compared amrinone with milrinone [60,62] and
one compared amrinone with enoximone [63]. None of these
studies found significant differences in haemodynamic
profiles. A further two randomized trials [5,8] compared
amrinone and epinephrine; in both these studies amrinone
produced a similar increase in CI and SVI, with significantly
greater reductions in SVR.
Jenkins and coworkers [34] conducted a randomized,
double-blind comparison of amrinone with dobutamine in 20
patients with severe pulmonary hypertension undergoing
mitral valve replacement. Amrinone was associated with a
reduction in pulmonary artery pressures and an increase in CI
and right ventricular ejection fraction compared with
dobutamine. Six patients in the dobutamine group suffered
postoperative myocardial infarctions, as opposed to none in
the amrinone group – a similar finding to that reported by
Dupuis and coworkers [39].
Our literature search returned only one study relating to the
effect of amrinone on vital organ perfusion. This was a
prospective, randomized study of 29 patients, reported by
Iribe and coworkers in 2000 [64]. That study compared the
effects of amrinone, milrinone and olprinone on hepatic
venous oxygen saturation. No significant change in hepatic
venous oxygen saturation was demonstrated in the amrinone
group (n =8 ) .
Although no studies used major clinical outcomes as primary
end-points, the study by Lewis and coworkers [57], the
largest randomized controlled trial, did not detect any
statistically significant difference in length of ICU or hospital
stay and mortality. The study by Butterworth and colleagues
[61] similarly found no difference in mortality between
amrinone and placebo groups.
Amrinone has been reported to impair coagulation because
of a reduction in platelet count and function [65,66], and
concerns over this have limited its use in some countries.
Enoximone
Enoximone is an imidazolone derivative phosphodiesterase-III
inhibitor. It is typically used in doses of 0.5–1.5 mg/kg
followed by an infusion of 5–10 µg/kg per min. It has a half-
life of 2 hours in normal patients but this may be prolonged in
patients with cardiac failure.
Of the 24 papers identified in our literature search, 19
investigated the effects of enoximone on systemic haemo-
dynamics in post-CPB patients. Of these 19 papers, two
were prospective, randomized, placebo-controlled trials.
Boldt and coworkers [67,68] conducted both of these
studies. The most recent of these studies [67] was
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published in 2002 and is a prospective, randomized,
blinded, placebo-controlled trial of 40 patients aged
80 years or older. The patients in that study received either
enoximone (bolus dose of 0.5 mg/kg followed by an infusion
of 2.5 µg/kg per min) or normal saline. Compared with
placebo, enoximone-treated patients recorded a significant
increase in CI (25.9%) and reduction in SVR (27.5%). No
significant differences in HR and MAP were recorded. In
1992, Boldt and coworkers [68] conducted a further
prospective, randomized, blinded, controlled study, again of
40 patients. Patients received either a single dose of
enoximone 1.0 mg/kg or served as controls. Enoximone
produced significant increases in CI (50%) and SVI
(28.8%), and decreases in SVR (45.3%) and PVR (30.4%).
No significant changes in HR and MAP were recorded.
Oxygen delivery and consumption were also significantly
higher in the enoximone group. Another study conducted by
Boldt and coworkers [69] compared 40 patients who had
received a single dose of enoximone 1.0 mg/kg with 40
historical controls. The enoximone-treated group required
significantly less epinephrine, calcium and nitroglycerin than
did the control group.
Several level II studies compared enoximone with other
inotropic agents, both catecholamines and other phospho-
diesterase-III inhibitors. One small, prospective, randomized
trial failed to show any significant haemodynamic differences
between amrinone and enoximone [62]. In the prospective,
randomized, blinded trial conducted by Tarr and coworkers in
75 patients [18], only in the enoximone group were all
patients successfully weaned from CPB, whereas three
patients from the dobutamine group and nine from the
dopamine group were withdrawn from the study because of
inadequate response. The enoximone group exhibited a
significantly lesser increase in HR and a greater increase in
stroke index than did either the dopamine or dobutamine
group, and also exhibited significantly a greater increase in CI
and decrease in SVR in comparison with dopamine.
Birnbaum and coworkers [70] conducted an earlier,
prospective, randomized, blinded comparison of enoximone
(two boluses of 0.5 mg/kg followed by an infusion of 5 µg/kg
per min) with dopamine (3.0–4.0 µg/kg per min) in 20
patients and obtained similar results.
As previously mentioned, we were able to find a further five
studies comparing enoximone with dobutamine. The largest
of these studies is the previously cited study conducted by
Zeplin and coworkers [44]. That study (n = 50) found that
enoximone significantly increased CI in comparison with
dobutamine.
Two small, randomized, controlled trials investigated the
effect of enoximone on vital organ perfusion. These showed
no effect on pHi and significant reductions in endotoxin
release [71], interleukins and α1-microglobulin in the
enoximone-treated group [67]. Two randomized controlled
trials (n = 80 and n = 36) [72,73] investigated the effects of
enoximone on coagulation parameters and platelet count and
function, and found no difference from control groups.
Finally, in a prospective trial [74] 88 elective CABG patients
were randomly pretreated with enoximone, clonidine,
enalalapril, or placebo. The enoximone-treated group exhibited
lower troponin T and creatine kinase-MB levels compared with
clonidine or placebo [74].
There are no data regarding the effect of enoximone on major
clinical outcomes or survival other than those from the study
conducted by Boldt and coworkers in 2002 [67], which
found that tracheal extubation was performed significantly
earlier in the enoximone-treated group.
Milrinone
Milrinone is a bipyridine methyl carbo-nitryl phospho-
diesterase-III inhibitor. Loading doses of 20–50 µg/kg are
typically given, followed by an infusion of 0.2–0.75 µg/kg per
min. It has a half-life of 30–60 min.
Our literature search identified 29 papers relating to the use
of milrinone in adults after cardiac surgical procedures. These
papers are summarized in Table 3. Nineteen of the papers
provided data on the haemodynamic effects of milrinone
following cardiac surgery and 14 of the papers were
prospective randomized trials.
Four prospective randomized trials [60,75,83,85] demon-
strated the effectiveness of milrinone compared with
placebo for weaning from CPB. In the study by Doolan and
coworkers [85], all patients in the milrinone group (n = 15)
were successfully weaned from CPB, as compared with only
five out of the 15 in the group randomly assigned to placebo.
In their prospective, blinded, randomized controlled trial,
Yamada and coworkers [80] compared two groups of 24
patients with low and normal pre-CPB CI. In both these
groups, the patients randomly assigned to milrinone
exhibited significantly higher CI (46% in the low pre-CPB CI
group) and significantly lower SVR (52% in the low pre-CPB
CI group) than controls. HR was not significantly affected,
but six out of 12 patients with a low CI required
norepinephrine to maintain adequate systemic blood
pressure. Similarly, Lobato and coworkers [83] found that a
single dose of milrinone 50 mg/kg administered before
separation from CPB significantly increased CI (43%) and
decreased SVR and catecholamine requirement compared
with placebo in 21 patients with pre-existing left ventricular
dysfunction. Again, more patients in the milrinone group
required vasopressor support. Kikura and Sato [60] obtained
similar results with milrinone, and these effects were
sustained into the first 24 hours after surgery.
Milrinone has been compared with catecholamines for
postoperative support in LCOS, notably by the European
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Table 3
Summary of literature search results for milrinone
Level of 
Ref. n Year Study design evidence Comparator Dose End-points
[60]a 45 2002 Prospective, blinded, randomized  II Amrinone/placebo 50 µg/kg then  Haemodynamic parameters
controlled trial 0.5 µg/kg per min
[75] 20 2002 Observational study III – 20 µg/kg Haemodynamic parameters
[76] 20 2002 Observational study III – 50 µg/kg Middle cerebral artery flow
[2]b,c 120 2001 Multicentre, prospective,  I Dobutamine 50 µg/kg then  Haemodynamic parameters
randomized trial 0.5 µg/kg per min
[77]b 20 2001 Prospective, blinded, randomized  II Control 0.5 µg/kg per min Haemodynamic parameters
controlled trial
[78] 20 2001 Prospective, randomized,  II Placebo 0.25 µg/kg per min pHi, inflammatory markers
placebo-controlled trial
[64]b 29 2000 Prospective, randomized trial II Amrinone, olprinone 50 µg/kg pHi, hepatic blood flow, 
oxygenation
[79]c 45 2000 Prospective, randomized trial II NO 50 µg/kg then  Haemodynamic parameters; 
0.5 µg/kg per min RVEF
[9] 20 2000 Prospective, randomized trial II Epinephrine 50 µg/kg Haemodynamic parameters
[80] 48 2000 Prospective, blinded, randomized,  II Placebo 20 µg/kg then  Haemodynamic parameters
placebo-controlled trial 0.2 µg/kg per min
[13]b 20 2000 Prospective, randomized trial II Epinephrine 50 µg/kg IMA flow
[81] 24 1999 Prospective, randomized controlled trial II Control 50 µg/kg Inflammatory markers
[27]b 24 1999 Prospective, blinded, randomized,  Dopamine,  50 µg/kg then  pHi, SHVO2, endotoxin levels
placebo-controlled trial II placebo 0.375 µg/kg per min
[82]b 22 1999 Prospective, randomized,  II Placebo 30 µg/kg then  Haemodynamic parameters 
placebo-controlled trial 0.5 µg/kg per min pHi, SHVO2, inflammatory 
markers
[83]a,c 21 1998 Prospective, blinded, randomized,  II Placebo 50 µg/kg Haemodynamic parameters
placebo-controlled trial
[62]b 44 1998 Prospective, multicentre, randomized trial II Amrinone Two boluses of 25 µg/kg Haemodynamic parameters
[84]b 37 1997 Prospective, randomized controlled trial II Control 50/75 µg/kg then  Haemodynamic parameters
0.5/0.75 µg/kg per min
[85]a,c 32 1997 Prospective, blinded, randomized,  II Placebo 50 µg/kg then  Haemodynamic parameters
placebo-controlled trial 0.5 µg/kg per min
[86]b 24 1996 Observational study III – 25–75 µg/kg then  Haemodynamic parameters
0.5 µg/kg per min for 1 hour
[87]b 29 1995 Observational study III – 25–75 µg/kg Haemodynamic parameters
[88]a 20 1995 Prospective, blinded, randomized trial II – 20 and 40 µg/kg then  Haemodynamic parameters
0.5 µg/kg per min
[89]b 25 1994 Observational study III – 25, 50, 75 µg/kg or  Plasma concentration
0.5 µg/kg per min
[90]b,c 12 1994 Observational study III – 50 µg/kg then  Plasma concentration
0.5 µg/kg per min
[91, 99 1992 Observational study III – 50 µg/kg then  Haemodynamic parameters
92]b,c 0.375–0.75 µg/kg per min
[93]b,c 24 1992 Observational study III – 50 µg/kg then  Haemodynamic parameters
0.375–0.75 µg/kg per min
[94]b,c 35 1991 Observational study III – 50 µg/kg then  Haemodynamic parameters
0.375–0.75 µg/kg per min
aWeaning from cardiopulmonary bypass. bPostoperative support. cCardiac index < 2.5 l/min per m2 or preoperative left ventricular ejection fraction < 0.4.
IMA, internal mammary artery; NO, nitric oxide; pHi, intramucosal pH; RVEF, right ventricular ejection fraction; SHVO2, hepatic vein oxygen saturation.275
Milrinone Multicentre Trial Group, which published the results
of a randomized, open label, multicentre study of 120
patients treated with milrinone or dobutamine for LCOS after
cardiac surgery [2]. The significant findings of this study are
described above in the section on dobutamine.
As previously mentioned, two studies [60,62] compared
amrinone with milrinone. Neither of these studies found
significant differences in haemodynamic profiles.
Solina and coworkers [79] compared the use of milrinone
with nitric oxide (NO) in cardiac surgery patients with
pulmonary hypertension. Those investigators found that the
effects of milrinone on right ventricular ejection fraction were
comparable with NO at 20 ppm but significantly less effective
than NO at 40 ppm.
Small randomized controlled trials [27,64,78,81] have
examined the effects of milrinone on pHi, splanchnic blood
flow and inflammatory markers. Two of these [78,81]
suggested that the administration of milrinone may attenuate
the fall in pHi associated with CPB and the increase in some
markers of inflammation. The remaining studies showed no
difference.
In a prospective, randomized study of 20 patients conducted
by Lobato and coworkers [13], milrinone produced a 24%
increase in grafted IMA flow, as measured by laser Doppler
flowmetry. In an observational study of 25 patients [76]
milrinone also increased cerebral blood flow, as measured by
transcranial Doppler, after separation from CPB.
We were unable to find any data relating to the effect of
milrinone on major clinical outcomes or survival in cardiac
surgery patients.
Levosimendan
There is little published work on the use of the novel calcium
sensitizer levosimendan in cardiac surgical patients with
LCOS. Levosimendan is a new inodilator that exerts its
inotropic effect by interacting with troponin C (the binding
protein for calcium) to enhance the calcium sensitivity of
cardiac myocytes.
In a multicentre, randomized, double-blind trial of 203 patients
[95], the efficacy and safety of levosimendan were compared
with those of dobutamine in severe low-output heart failure
(the LIDO study). Levosimendan improved haemodynamic
performance more effectively than did dobutamine in patients
with severe, low-output heart failure, and there was
significantly lower mortality in the levosimendan group.
However, only 2–4% of the study population had
postoperative cardiac failure. A recent uncontrolled pilot study
in cardiac surgery patients with LCOS found that
levosimendan increased CI and stroke volume while lowering
pulmonary artery occlusion pressure [96].
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Table 4
Summary of literature search findings
Total number  ‘Level I’  ‘Level II’ 
Agent of studies studies studies Significant findings
Epinephrine 15 0 10 Increases CI with biphasic effect on SVR index. Produces rise in serum 
lactate
Dopamine 22 0 14 Increased SVR index at doses above 5.0 µg/kg per min. Less clinical 
efficacy than dobutamine, dopexamine, amrinone, or enoximone. 
Increased incidence of adverse cardiac events than with dopexamine
Dobutamine 23 0 18 Better efficacy than dopamine and epinephrine. Decreases SVR index. 
Tachycardia and tachyarrythmia (especially AF) associated with use. 
More ischaemic complications than with amrinone
Dopexamine 20 12 Greater tachycardia than with dobutamine. More efficacious and fewer 
adverse events than with dopamine.
Amrinone 27 1 13 Improved weaning from CPB. Improves CI and decreases SVR index 
with minimal effects on HR. Fewer ischaemic complications than with 
dobutamine. Reports of thrombocytopenia associated with use
Enoximone 24 0 15 Significant increase in CI without tachycardia. Decreases SVR index. 
As effective as dobutamine
Milrinone 27 0 17 Significant increase in CI without tachycardia. Decreases SVR index. 
As effective as dobutamine but less AF. Luistropic. Improves IMA graft 
flow. As effective as 20 ppm NO in pulmonary hypertension
AF, atrial fibrillation; CI, cardiac index; CPB, cardiopulmonary bypass; HR, heart rate; IMA, internal mammary artery; NO, nitric oxide; SVR, systemic
vascular resistance.276
Conclusion
It is well recognized that myocardial dysfunction occurs after
cardiac surgery. Because LCOS is common, contributes to
morbidity and mortality, and increases length of ICU and
hospital stay and costs, it is desirable to minimize its
occurrence or attenuate its severity. A summary of the
significant findings of our literature review are presented in
Table 4. It is evident that there are two main classes of
inotropic agents that should be used for support of cardiac
output after cardiac surgery: catecholamines and PDIs (data
for use of calcium sensitizers in this setting is scant).
Moreover, all of these agents have been demonstrated to be
effective at improving myocardial contractility or HR, or both.
Although some reports in the literature suggest that
catecholamines are more potent inotropic and chronotropic
agents, serious drawbacks associated with their use include
increased myocardial oxygen consumption, tachycardia,
increased afterload and arrhythmias. β-Adrenergic receptors
may also be downregulated in patients with pre-existing
cardiac failure. This has led to interest in the use of
phosphodiesterase-III inhibitors and, more recently, the
calcium sensitizer levosimendan.
Studies investigating the use of PDIs in cardiac surgery have
shown them to be potent inotropes, but vasodilation is a
prominent feature of their use, and so concomitant
administration of a vasoconstrictor such as norepinephrine or
phenylephrine is often required. Such vasoconstrictor agents
may or may not have adverse effects of their own. The effects
of PDIs on HR appear to be minimal, and there is evidence to
suggest that diastolic relaxation and flow through arterial
grafts is improved. However, because of their pharmaco-
kinetic profile, the time of onset and offset are longer (a
loading dose is required) and they have the potential to
accumulate in renal failure. These features can render the
PDIs clinically less practical.
The effect of using either catecholamines or PDIs on major
clinical outcomes or survival is unknown. We conducted an
extensive literature search for data reported during the past
20 years relating to the use of inotropic agents in adult
patients who have undergone cardiac surgery. Perhaps the
most important finding of this review is the lack of large,
double-blind, randomized controlled trials focusing on
important clinical outcomes for drugs that are probably given
to 250,000–500,000 people each year in western countries
alone. Of course, there is overwhelming evidence that the
agents considered in this review increase cardiac output, but
the question of their comparative effects in the post-CPB
heart and their effects on important clinical outcomes remains
unclear. The available evidence is often not homogenous and
is completely unsuitable for meta-analysis. Also, many of the
data rely on physiological end-points, and there are clearly
inherent pitfalls in this. Of 125 retrieved papers, only one
‘level I’ study was identified. The study by Feneck and
coworkers [2] provides the only direct comparison between
catecholamines and PDIs in patients with LCOS. A summary
of haemodynamic changes between the milrinone group and
the dobutamine group from the study is outlined in Fig. 2.
Although that study included a reasonably large number of
patients (n = 120), no convincing advantage was shown for
either drug. Moreover, the observation period was only
4 hours and the outcomes were only physiological. This is
disappointing because there are several theoretical
advantages of PDIs over catecholamines: less tachycardia
and myocardial oxygen consumption, improved diastolic
relaxation, peripheral and pulmonary vasodilation, and
increased IMA graft flow. On the other hand, such
advantages are theoretically diminished by the need for
vasopressor support.
Hoffman and coworkers recently reported the findings of the
PRIMACORP study [97], a randomized, blinded, placebo-
controlled trial that investigated the efficacy and safety of
prophylactic milrinone in paediatric patients at risk for
developing LCOS. Of the 239 patients investigated, high-
dose milrinone (75 µg/kg per min followed by an infusion of
0.75 µg/kg per min) reduced the risk for LCOS by 48%. A
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Figure 2
Summary of the haemodynamic changes that occur in the first 4 hours
after treatment with milrinone or dobutamine [2]. All differences are
presented as percentage change from baseline and are statistically
significant. (a) The positive changes indicate an increase in heart rate
(HR) and a decrease in pulmonary artery occlusion pressure (PAOP)
with either milrinone (M) or dobutamine (D). (b) The changes represent
the increases in cardiac index (CI) and mean arterial pressure (MAP)
with milrinone (M) and dobutamine (D).
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randomized controlled study of suitable statistical power must
be conducted to compare fully the benefits of PDIs with
those of dobutamine in adult cardiac surgical patients, with
the focus on clinical rather than just physiological outcomes.
Following our systematic analysis of the literature, we believe
that – despite the limitations of the data – some
recommendations can be made, each with a particular level
of evidence.
• Recommendation 1 (level C). β-Agonists or PDIs are
more efficacious at increasing cardiac output than
placebo for the treatment of LCOS after cardiac surgery.
Beta-agonists are associated with a greater incidence of
tachycardia and tachyarrhythmia. Administration of a
vasoconstrictor is often required with PDIs.
• Recommendation 2 (level C). Catecholamines such as
dopamine, epinephrine and dopexamine have no clear
advantages over dobutamine and may be associated with
a greater incidence of adverse effects. Epinephrine has
been successfully used as salvage therapy.
• Recommendation 3 (level C). Administration of PDIs
before separation from CPB increases the likelihood of
successful weaning compared with placebo, and
decreases the use of catecholamines during the
postoperative period. Concerns regarding amrinone and
thrombocytopenia have limited its use.
• Recommendation 4 (level C). There is no evidence that
inotropes should be selected for their effects on regional
perfusion.
• Recommendation 5 (level C). Administration of milrinone
increases flow through arterial grafts.
• Recommendation 6 (level C). Milrinone and probably
other PDIs reduce mean pulmonary artery pressure and
improve right heart performance in pulmonary hypertension.
We believe that the field of clinical research into inotropic
support for adult cardiac surgery has reasonably established
the superiority of catecholamines and PDIs over placebo.
However, insufficient evidence exists to guide the choice of
one group of drugs versus the other. The role of the new
calcium sensitizers remains unknown. It is biologically
plausible that the use of catecholamines or PDIs may lead to
different clinical outcomes and the clinical scenario of LCOS
is relatively common, and so suitably powered, multicentre,
randomized controlled trials should be a clinical research
priority in adult cardiac surgery patients.
Competing interests
The author(s) declare that they have no competing interests.
References
1. Boldt J, Hammermann H, Hempelmann G: What is the place of
the phosphodiesterase inhibitors? Eur J Anaesthiol Suppl
1993, 8:33-37.
2. Feneck RO, Sherry KM, Withington PS, Oduro-Dominah A, Euro-
pean Milrinone Multicenter Trial Group: Comparison of the
haemodynamic effects of milrinone with dobutamine in
patients after cardiac surgery. J Cardiothorac Vasc Anesth
2001, 15:306-315.
3. Polonen P, Ruokonen E, Hippelainen M, Poyhonen M, Takala J: A
prospective, randomised study of goal-oriented haemody-
namic therapy in cardiac surgical patients. Anesth Analg 2000,
90:1052-1059.
4. Cook DJ, Guyatt GH, Laupacis A, Sackett DL: Rules of evidence
and clinical recommendations on the use of antithrombotic
agents. Chest 1992, 102:305S-311S.
5. Gunnicker M, Brinkmann M, Donovan TJ, Freund U, Schieffer M,
Reidemeister JC: The efficacy of amrinone or adrenaline on
low cardiac output following cardiopulmonary bypass in
patients with coronary artery disease undergoing preopera-
tive beta-blockade. Thorac Cardiovasc Surg 1995, 43:153-160.
6. Royster RL, Butterworth JF 4th, Prielipp RC, Robertie PG, Kon
ND, Tucker WY, Dudas LM, Zaloga GP: A randomised, blinded,
placebo controlled evaluation of calcium chloride and epi-
nephrine for inotropic support after emergence from car-
diopulmonary bypass. Anesth Analg 1992, 74:3-13.
7. Linton NW, Linton RA: Haemodynamic response to a small
intravenous bolus injection of epinephrine in cardiac surgical
patients. Eur J Anaesthesiol 2003, 20:298-304.
8. Royster RL, Butterworth JF 4th, Prielipp RC, Zaloga GP, Lawless
SG, Spray BJ, Kon ND, Wallenhaupt SL, Cordell AR: Combined
inotropic effects of amrinone and epinephrine after cardiopul-
monary bypass in humans. Anesth Analg 1993, 77:662-672.
9. Lobato EB, Gravenstein N, Martin TD: Milrinone, not epineph-
rine, improves left venticular compliance after cardiopul-
monary bypass. J Cardiothorac Vasc Anesth 2000, 14:374-377.
10. Butterworth JF 4th, Prielipp RC, Royster RL, Spray BJ, Kon ND,
Wallenhaupt SL, Zaloga GP: Dobutamine increases heart rate
more than epinephrine in patients recovering from aortocoro-
nary bypass surgery. J Cardiothorac Vasc Anesth 1992, 6:535-
541.
11. Balderman SC, Aldridge J: Pharmacologic support of the
myocardium following aortocoronary bypass surgery: a com-
parative study. J Clin Pharmacol 1986, 26:175-183.
12. Totaro RJ, Raper RF: Epinephrine-induced lactic acidosis fol-
lowing cardiopulmonary bypass. Crit Care Med 1997,  25:
1693-1699.
13. Lobato EB, Urdaneta F, Martin TD, Gravenstein N: Effects of mil-
rinone versus epinephrine on grafted internal mammary
artery flow after cardiopulmonary bypass. J Cardiothorac Vasc
Anesth 2000, 14:9-11.
14. Cracowski JL, Chavanon O, Durand M, Borrel E, Devillier P,
Mallion JM, Blin D: Effect of low-dose positive inotropic drugs
on human internal mammary artery flow. Ann Thorac Surg
1997, 64:1742-1746.
15. DiNardo JA, Bert A, Schwartz MJ, Johnson RG, Thurer RL, Wein-
traub RM: Effects of vasoactive drugs on flows through left
internal mammary artery and saphenous vein grafts in man. J
Thorac Cardiovasc Surg 1991, 102:730-735.
16. Salomon NW, Plachetka JR, Copeland JG: Comparison of
dopamine and dobutamine following coronary artery bypass
grafting. Ann Thorac Surg 1982, 33:48-54.
17. Rosseel PM, Santman FW, Bouter H, Dott CS: Postcardiac
surgery low cardiac output syndrome: dopexamine or
dopamine? Intensive Care Med 1997, 23:962-968.
18. Tarr TJ, Moore NA, Frazer RS, Shearer ES, Desmond MJ: Haemo-
dynamic effects and comparison of enoximone, dobutamine
and dopamine following mitral valve surgery. Eur J Anaesthe-
siol Suppl 1993, 8:15-24.
19. Davis RF, Lappas DG, Kirklin JK, Buckley MJ, Lowenstein E:
Acute oliguria after cardiopulmonary bypass: renal functional
improvement with low-dose dopamine infusion. Crit Care Med
1982, 10:852-856.
20. Woo EB, Tang AT, El-Gamel A, Keevil B, Greenhalgh D, Patrick
M, Jones MT, Hooper TL: Dopamine therapy for patients at risk
of renal dysfunction following cardiac surgery: science or
fiction? Eur J Cardiothorac Surg 2002, 22:106-111.
21. Tang AT, El-Gamel A, Keevil B, Yonan N, Deiraniya AK: The effect
of ‘renal-dose’ dopamine on renal tubular function following
cardiac surgery: assessed by measuring retinol binding
protein (RBP). Eur J Cardiothorac Surg 1999, 15:717-721, dis-
cussion 721-722.
22. Lema G, Urzua J, Jalil R, Canessa R, Moran S, Sacco C, Medel J,
Irarrazaval M, Zalaquett R, Fajardo C, et al.: Renal protection in
patients undergoing cardiopulmonary bypass with preopera-
tive abnormal renal function. Anesth Analg 1998, 86:3-8.
Available online http://ccforum.com/content/9/3/266278
Critical Care    June 2005 Vol 9 No 3 Gillies et al.
23. Myles PS, Buckland MR, Schenk NJ, Cannon GB, Langley M,
Davis BB, Weeks AM: Effect of ‘renal-dose’ dopamine on renal
function following cardiac surgery. Anaesth Intensive Care
1993, 21:56-61.
24. Jakob SM, Ruokonen E, Takala J: Effects of dopamine on sys-
temic and regional blood flow and metabolism in septic and
cardiac surgery patients. Shock 2002, 18:8-13.
25. Jakob SM, Ruokonen E, Rosenberg PH,Takala J: Effect of
dopamine induced changes in splanchnic blood flow on
MEGX production from lidocaine in septic and cardiac surgery
patients. Shock 2002, 18:1-7.
26. Thoren A, Elam M, Ricksten SE: Differential effects of
dopamine, dopexamine and dobutamine on jejunal mucosal
perfusion early after cardiac surgery. Crit Care Med 2000, 28:
2338-2343.
27. McNicol L, Andersen LW, Liu G, Doolan L, Baek L: Markers of
splanchnic perfusion and intestinal translocation of endotox-
ins during cardiopulmonary bypass: effects of dopamine and
milrinone. J Cardiothorac Vasc Anesth 1999, 13:292-298.
28. Gardeback M, Settergren G: Dopexamine and dopamine in the
prevention of low gastric mucosal pH following cardiopul-
monary by-pass. Acta Anaesthesiol Scand 1995,  39:1066-
1070.
29. Schneider M, Valentine S, Hegde RM, Peacocks J, March S,
Dobb GJ: The effect of different bypass flow rates and low-
dose dopamine on gut mucosal perfusion and outcome in
cardiac surgical patients. Anaesth Intensive Care 1999, 27:13-
19.
30. Vaisanen O, Ruokonen E, Parviainen I, Bocek P, Takala J: Raniti-
dine or dobutamine alone or combined has no effect on
gastric intramucosal-arterial PCO(2) difference after cardiac
surgery. Intensive Care Med 2000, 26:45-51.
31. Ensinger H, Rantala A, Vogt J, Georgieff M, Takala J: Effect of
dobutamine on splanchnic carbohydrate metabolism and
amino acid balance after cardiac surgery. Anesthesiology
1999, 91:1587-1595.
32. Romson JL, Leung JM, Bellows WH, Bronstein M, Keith F, Moores
W, Flachsbart K, Richter R, Pastor D, Fisher DM: Effects of
dobutamine on hemodynamics and left ventricular perfor-
mance after cardiopulmonary bypass in cardiac surgical
patients. Anesthesiology 1999, 91:1318-1328.
33. Hachenberg T, Mollhoff T, Holst D, Hammel D, Brussel T: Car-
diopulmonary effects of enoximone or dobutamine and nitro-
glycerin on mitral valve regurgitation and pulmonary venous
hypertension. J Cardiothorac Vasc Anesth 1997, 11:453-457.
34. Jenkins IR, Dolman J, O’Connor JP, Ansley DM: Amrinone versus
dobutamine in cardiac surgical patients with severe pul-
monary hypertension after cardiopulmonary bypass: a
prospective, randomized double-blinded trial. Anaesth Inten-
sive Care 1997, 25:245-249.
35. Vroom MB, van Wezel HB, vd Brink RB, vd Lee R, Eijsman L,
Visser CA, van Zwieten PA: Effects of dobutamine and enoxi-
mone on transmitral and pulmonary venous flow characteris-
tics in patients with left ventricular dysfunction after coronary
artery bypass grafting. J Cardiothorac Vasc Anesth 1996, 10:
756-763.
36. Parviainen I, Ruokonen E, Takala J: Dobutamine-induced disso-
ciation between changes in splanchnic blood flow and gastric
intramucosal pH after cardiac surgery. Br J Anaesth 1995, 74:
277-282.
37. MacGregor DA, Butterworth JF 4th, Zaloga CP, Prielipp RC,
James R, Royster RL: Hemodynamic and renal effects of
dopexamine and dobutamine in patients with reduced cardiac
output following coronary artery bypass grafting. Chest 1994,
106:835-841.
38. Ruokonen E, Takala J, Kari A: Regional blood flow and oxygen
transport in patients with the low cardiac output syndrome
after cardiac surgery. Crit Care Med 1993, 21:1304-1311.
39. Dupuis JY, Bondy R, Cattran C, Nathan HJ, Wynands JE: Amri-
none and dobutamine as primary treatment of low cardiac
output syndrome following coronary artery surgery: a compar-
ison of their effects on hemodynamics and outcome. J Cardio-
thorac Vasc Anesth 1992, 6:542-553.
40. Imai T, Saitoh K, Kani H, Fujita T, Murata K: Combined dose
ratios of dopamine and dobutamine and right ventricular per-
formance after cardiac surgery. Chest 1992, 101:1197-1202
41. Boldt J, Kling D, Zickmann B, Dapper F, Hempelmann G: Haemo-
dynamic effects of the phosphodiesterase inhibitor enoxi-
mone in comparison with dobutamine in esmolol-treated
cardiac surgery patients. Br J Anaesth 1990, 64:611-616.
42. Keogh B, Priddy R, Morgan C, Gillbe C: Comparative study of
the effects of enoximone and dobutamine in patients with
impaired left ventricular function undergoing cardiac surgery.
Cardiology 1990, Suppl 3:58-61.
43. Orellano L, Darwisch M, Dieterich HA, Kollner V: Comparison of
dobutamine and enoximone for low output states following
cardiac surgery. Int J Cardiol 1990, Suppl 1:S13-S19.
44. Zeplin HE, Dieterich HA, Stegmann T: The effect of enoximone
and dobutamine on hemodynamic performance after open-
heart surgery. A clinical comparison. J Cardiovasc Surg 1990,
31:574-577.
45. DiSesa VJ, Gold JP, Shemin RJ, Collins JJ Jr, Cohn LH: Compari-
son of dopamine and dobutamine in patients requiring post-
operative circulatory support. Clin Cardiol 1986, 9:253-256.
46. Smith GW, Filek SAL: Dopexamine hydrochloride: a novel
dopamine receptor agonist for the acute treatment of low
output states. Cardiovasc Drug Rev 1989, 7:141-159.
47. Hurley J, McDonagh P, Cahill M, White M, Luke D, McGovern E,
Phelan D: The haemodynamic effect of prophylactic peri-oper-
ative dopexamine in coronary artery bypass patients. Eur
Heart J 1995, 16:1705-1709.
48. Sherry E, Tooley MA, Bolsin SN, Monk CR, Willcox J: Effect of
dopexamine hydrochloride on renal vascular resistance index
and haemodynamic responses following coronary artery
bypass graft surgery. Eur J Anaesthesiol 1997, 14:184-189.
49. Honkonen EL, Kaukinen L. Kaukinen S, Pehkonen EJ, Laippala P:
Dopexamine unloads the impaired right ventricle better than
iloprost, a prostacyclin analog, after coronary artery surgery. J
Cardiothorac Anesth 1998, 12:647-653.
50. Berendes E, Mollhoff T, Van Aken H, Schmidt C, Erren M, Deng
MC, Weyand M, Loick HM: Effects of dopexamine on creati-
nine clearance, systemic inflammation, and splanchnic oxy-
genation in patients undergoing coronary artery bypass
grafting. Anesth Analg 1997, 84:950-957.
51. Dehne MG, Klein TF, Muhling J, Sablotzki A, Osmer C, Hempel-
mann G: Impairment of renal function after cardiopulmonary
bypass is not influenced by dopexamine. Ren Fail 2001, 23:
217-230.
52. Stephan H, Sonntag H, Henning H, Yoshimine K: Cardiovascular
and renal haemodynamic effects of dopexamine: comparison
with dopamine. Br J Anaesth 1990, 65:380-387.
53. Sinclair DG, Houldsworth PE, Keogh B, Pepper J, Evans TW: Gas-
trointestinal permeability following cardiopulmonary bypass: a
randomized study comparing the effects of dopamine and
dopexamine. Intensive Care Med 1997, 23:510-516.
54. Uusaro A, Ruokonen E, Takala J: Gastric mucosal pH does not
reflect changes in splanchnic blood flow after cardiac surgery.
Br J Anaesth 1995, 74:149-154.
55. Sharpe DA, Mitchel IM, Kay EA, McGoldrick JP, Munsch CM, Kay
PH: Enhancing liver blood flow after cardiopulmonary bypass:
the effects of dopamine and dopexamine. Perfusion 1999, 14:
29-36.
56. Bailey JM, Levy JH, Rogers HG, Szlam F, Hug CC Jr: Pharmaco-
kinetics of amrinone during cardiac surgery. Anesthesiology
1991, 75:961-968.
57. Lewis KP, Appadurai IR, Pierce ET, Halpern EF, Bode RH Jr: Pro-
phylactic amrinone for weaning from cardiopulmonary
bypass. Anaesthesia 2000, 55:627-633.
58. Ramsay JG, DeJesus JM, Wynands JE, Ralley FE, O’Connor JP,
Robbins GR, Bilodeau J: Amrinone before termination of car-
diopulmonary bypass: haemodynamic variables and oxygen
utilization in the post postbypass period. Can J Anaesth 1992,
39:342-348.
59. Badner NH, Murkin JM, Shannon NA: An amrinone bolus prior
to weaning from cardiopulmonary bypass improves cardiac
function in mitral valve surgery patients. J Cardiothorac Vasc
Anaesth 1994, 8:410-414.
60. Kikura M, Sato S: The efficacy of preemptive milrinone or amri-
none therapy in patients undergoing coronary artery bypass
grafting. Anesth Analg 2002, 94:22-30.
61. Butterworth JF 4th, Royster RL, Prielipp RC, Lawless ST, Wallen-
haupt SL: Amrinone in cardiac surgical patients with left-ven-
tricular dysfunction. A prospective, randomized placebo-
controlled trial. Chest 1993, 104:1660-1667.279
Available online http://ccforum.com/content/9/3/266
62. Rathmell JP, Prielipp RC, Butterworth JF, Williams E, Villamaria F,
Testa L, Viscomi C, Ittleman FP, Baisden CE, Royster RL: A mul-
ticenter, randomized, blind comparison of amrinone with mil-
rinone after elective cardiac surgery. Anesth Analg 1998, 86:
683-690.
63. Zerkowski HR, Gunnicker M, Freund U, Dieterich HA, Dressler
HT, Doetsch N, Schieffer M, Hakim-Meibodi K, Lockhart JD, Rei-
demeister JC: Low output syndrome after heart surgery: is a
monotherapy with phosphodiesterase-III inhibitors feasible?
A comparitive study of amrinone and enoximone. Thorac Car-
diovasc Surg 1992, 40:371-377.
64. Iribe G, Yamada H, Matsunaga A, Yoshimura N: Effects of the
phosphodiesterase III inhibitors olprinone, milrinone, and
amrinone on hepatosplanchnic oxygen metabolism. Crit Care
Med 2000, 28:743-748.
65. Ansell J, Tiarks C, McCue J, Parrilla N, Benotti JR: Amrinone-
induced thrombocytopenia. Arch Intern Med 1984,  144:949-
952.
66. Gunnicker M, Hess W: Preliminary results with amrinone in
perioperative low cardiac output syndrome. Thorac Cardiovasc
Surg 1987, 35:219-225.
67. Boldt J, Brosch C, Suttner S, Piper SN, Lehmann A, Werling C:
Prophylactic use of the phospodiesterase III inhibitor enoxi-
mone in elderly cardiac surgery patients: effect on hemody-
namics, inflammation, and markers of organ function.
Intensive Care Med 2002, 28:1462-1469.
68. Boldt J, Knothe C, Zickmann B, Ballesteros M, Russ W, Dapper F,
Hempelmann G: The role of enoximone in cardiac surgery. Br J
Anaesth 1992, 69:45-50.
69. Boldt J, Kling D, Zickmann B, Dapper F, Hempelmann G: Efficacy
of the phosphodiesterase inhibitor enoximone in complicated
cardiac surgery. Chest 1990, 98:53-58.
70. Birnbaum DE, Preuner JG, Gieseke R, Trenk D, Jaehnehan E:
Enoximone versus dopamine in patients being weaned from
cardiopulmonary bypass. Cardiology 1990,  Suppl 3: 34-41;
discussion: 62-67.
71. Loick HM, Mollhoff T, Berendes E, Hammel D, Van Aken H: Influ-
ence of enoximone on systemic and splanchnic oxygen uti-
lization and endotoxin release following cardiopulmonary
bypass. Intensive Care Med 1997, 23:267-275.
72. Boldt J, Knothe C, Zickmann B, Herold C, Dapper E, Hempelmann
G: Phosphodiesterase-inhibitors enoximone and piroximone
in cardiac surgery: influence on platelet count and function.
Intensive Care Med 1992, 18:449-454.
73. Boldt J, Kling D, Dieterich HA, Marck P, Hempelmann G: The new
phosphodiesterase inhibitor enoximone in patients following
cardiac surgery: pharmacokinetics and influence on parame-
ters of coagulation. Intensive Care Med 1990, 16:54-59.
74. Boldt J, Rothe G, Schindler E, Doll C, Gorlach G, Hempelmann
G: Can clonidine, enoximone, and enalaprilat help to protect
the myocardium against ischaemia in cardiac surgery? Heart
1996, 76:207-213.
75. De Hert SG, ten Broecke PW, Mertens E, Rodrigus IE, Stockman
BA:  Effects of phosphodiesterase III inhibition on length-
dependent regulation of myocardial function in coronary
surgery patients. Br J Anaesth 2002, 88:779-784.
76. Sulek CA, Blas ML, Lobato EB: Milrinone increases middle
cerebral artery blood flow velocity after cardiopulmonary
bypass. J Cardiothorac Vasc Anesth 2002, 16:64-69.
77. Shibata T, Suehiro S, Sasaki Y, Hosono M, Nishi S, Kinoshita H:
Slow induction of milrinone after coronary artery bypass graft-
ing. Ann Thorac Cardiovasc Surg 2001, 7:23-27.
78. Yamaura K, Okamoto H, Akiyoshi K, Irita K, Taniyama T, Takahashi
S: Effect of low-dose milrinone on gastric intramucosal pH
and systemic inflammation after hypothermic cardiopul-
monary bypass. J Cardiothorac Vasc Anesth 2001, 15:197-203.
79. Solina A, Papp D, Ginsberg S, Krause T, Grubb W, Scholz P,
Pena LL, Cody R: A comparison of inhaled nitric oxide and mil-
rinone for the treatment of pulmonary hypertension in adult
cardiac surgery patients. J Cardiothorac Vasc Anesth 2000, 14:
12-17.
80. Yamada T, Takeda J, Katori N, Tsuzaki K, Ochiai R: Hemody-
namic effects of milrinone during weaning from cardiopul-
monary bypass: comparison of patients with a low and high
prebypass cardiac index. J Cardiothorac Vasc Anesth 2000, 14:
367-373.
81. Hayashida N, Tomoeda H, Oda T, Tayama E, Chihara S, Kawara
T, Aoyagi S: Inhibitory effect of milrinone on cytokine produc-
tion after cardiopulmonary bypass. Ann Thorac Surg 1999, 68:
1661-1667.
82. Mollhoff T, Loick HM, Van Aken H, Schmidt C, Rolf N, Tjan TD,
Asfour B, Berendes E: Milrinone modulates endotoxemia, sys-
temic inflammation, and subsequent acute phase response
after cardiopulmonary bypass (CPB). Anesthesiology 1999, 90:
72-80.
83. Lobato EB, Florete O Jr, Bingham HL: A single dose of milri-
none facilitates separation from cardiopulmonary bypass in
patients with pre-existing left ventricular dysfunction. Br J
Anaesth 1998, 81:782-184.
84. Kikura M, Levy JH, Michelsen LG, Shanewise JS, Bailey JM, Sadel
SM, Szlam F: The effect of milrinone on hemodynamics and
left ventricular function after emergence from cardiopul-
monary bypass. Anesth Analg 1997, 85:16-22.
85. Doolan LA, Jones EF, Kalman J, Buxton BF, Tonkin AM: A
placebo-controlled trial verifying the efficacy of milrinone in
weaning high-risk patients from cardiopulmonary bypass. J
Cardiothorac Vasc Anesth 1997, 11:37-41.
86. Prielipp RC, MacGregor DA, Butterworth JF 4th, Meredith JW,
Levy JH, Wood KE, Coursin DB: Pharmacodynamics and phar-
macokinetics of milrinone administration to increase oxygen
delivery in critically ill patients. Chest 1996, 109:1291-1301.
87. Butterworth JF 4th, Hines RL, Royster RL, James RL: A pharma-
cokinetic and pharmacodynamic evaluation of milrinone in
adults undergoing cardiac surgery. Anesth Analg 1995,  81:
783-792.
88. Kikura M, Lee MK, Safon RA, Bailey JM, Levy JH: The effects of
milrinone on platelets in patients undergoing cardiac surgery.
Anesth Analg 1995, 81:44-48.
89. Bailey JM, Levy JH, Kikura M, Szlam F, Hug CC Jr: Pharmacoki-
netics of intravenous milrinone in patients undergoing cardiac
surgery. Anesthesiology 1994, 81:616-622.
90. Das PA, Skoyles JR, Sherry KM, Peacock JE, Fox PA, Woolfrey
SG: Disposition of milrinone in patients after cardiac surgery.
Br J Anaesth 1994, 72:426-429.
91. Feneck RO: Intravenous milrinone following cardiac surgery:
II. Influence of baseline hemodynamics and patient factors on
therapeutic response. The European Milrinone Multicentre
Trial Group. J Cardiothorac Vasc Anesth 1992, 6:563-567.
92. Feneck RO: Intravenous milrinone following cardiac surgery: I.
Effects of bolus infusion followed by variable dose mainte-
nance infusion. The European Milrinone Multicentre Trial
Group. J Cardiothorac Vasc Anesth 1992, 6:554-562.
93. George M, Lehot JJ, Estanove S: Haemodynamic and biological
effects of intravenous milrinone in patients with a low cardiac
output syndrome following cardiac surgery: multicentre study.
Eur J Anaesthesiol 1992, 5:31-34.
94. Wright EM, Sherry KM: Clinical and haemodynamic effects of
milrinone in the treatment of low cardiac output after cardiac
surgery. Br J Anaesth 1991, 67:585-590.
95. Follath F, Cleland JG, Just H, Papp JG, Scholz H, Peuhkurinen K,
Harjola VP, Mitrovic V, Abdalla M, Sandell EP, et al.: Efficacy and
safety of intravenous levosimendan compared with dobuta-
mine in severe low-output heart failure (the LIDO study): a
randomized double-blind trial. Lancet 2002, 360:196-202.
96. Labriola C, Siro-Brigiani M, Carrata F, Santangelo E, Amantea B:
Hemodynamic effects of levosimendan in patients with low-
output heart failure after cardiac surgery. Int J Clin Pharmacol
Ther 2004, 42:204-211.
97. Hoffman TM, Wernovsky G, Atz AM, Kulik TJ, Nelson DP, Chang
AC, Bailey JM, Akbary A, Kocsis JF, Kaczmarek R, et al.: Efficacy
and safety of milrinone in preventing low cardiac output syn-
drome in infants and children after corrective surgery for con-
genital heart disease. Circulation 2003, 107:996-1002.